0001683168-24-006281.txt : 20240910 0001683168-24-006281.hdr.sgml : 20240910 20240910160518 ACCESSION NUMBER: 0001683168-24-006281 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240909 ITEM INFORMATION: Other Events FILED AS OF DATE: 20240910 DATE AS OF CHANGE: 20240910 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Sunshine Biopharma, Inc CENTRAL INDEX KEY: 0001402328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 205566275 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41282 FILM NUMBER: 241290115 BUSINESS ADDRESS: STREET 1: 333 LAS OLAS WAY STREET 2: CU4 SUITE 433 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 BUSINESS PHONE: 954-515-0810 MAIL ADDRESS: STREET 1: 333 LAS OLAS WAY STREET 2: CU4 SUITE 433 CITY: FORT LAUDERDALE STATE: FL ZIP: 33301 FORMER COMPANY: FORMER CONFORMED NAME: Mountain West Business Solutions, Inc DATE OF NAME CHANGE: 20071030 FORMER COMPANY: FORMER CONFORMED NAME: mountain west business solutions,inc DATE OF NAME CHANGE: 20070607 8-K 1 sunshine_8k.htm FORM 8-K 8-K
false 0001402328 0001402328 2024-09-09 2024-09-09 0001402328 us-gaap:CommonStockMember 2024-09-09 2024-09-09 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-09-09 2024-09-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 9, 2024

 

SUNSHINE BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 001-41282 20-5566275

(State or other jurisdiction

of incorporation)

 (Commission File Number) (IRS Employer ID No.)

 

333 Las Olas Way, CU4 Suite 433

Fort Lauderdale, FL 33301

(Address of principal executive offices) (zip code)

 

(954) 515-0810

(Registrant’s telephone number, including area code)

 

                            

(Former name or former address, if changed since last report.)

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading Symbol Name of Each Exchange on Which Registered
Common Stock, par value $0.001 SBFM The Nasdaq Stock Market LLC
Common Stock Purchase Warrants SBFMW The Nasdaq Stock Market LLC

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

   

 

 

Item 8.01 Other Events.

 

On September 9, 2024, Sunshine Biopharma, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with the bid price requirement in Listing Rule 5550(a)(2) (the “Bid Price Rule”), as required by the Hearing Panel’s (“Panel”) decision dated June 28, 2024.

 

The letter further states that the Company will be subject to a Mandatory Panel Monitor for a period of one year. If, within that one-year monitoring period, the Nasdaq Listing Qualifications staff (“Nasdaq Staff”) finds the Company again out of compliance with the Bid Price Rule, the Company will not be permitted to provide the Staff with a plan of compliance with respect to that deficiency and Staff will not be permitted to grant additional time for the Company to regain compliance with respect to that deficiency, nor will the Company be afforded an applicable cure or compliance period pursuant to Rule 5810(c)(3). Instead, the Nasdaq Staff will issue a Delist Determination Letter and the Company will have an opportunity to request a new hearing with the initial Panel or a newly convened Hearings Panel if the initial Panel is unavailable. The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C). The Company’s securities may be delisted from Nasdaq at that time.

 

 

 

 

 

 

 

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: September 10, 2024 SUNSHINE BIOPHARMA, INC.
   
   
  By: /s/ Dr. Steve N. Slilaty                                           
  Dr. Steve N. Slilaty, Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 3 
 EX-101.SCH 2 sbfm-20240909.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 3 sbfm-20240909_def.xml XBRL DEFINITION FILE EX-101.LAB 4 sbfm-20240909_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock [Member] Common Stock Purchase Warrants [Member] Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 sbfm-20240909_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Cover
Sep. 09, 2024
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 09, 2024
Entity File Number 001-41282
Entity Registrant Name SUNSHINE BIOPHARMA, INC.
Entity Central Index Key 0001402328
Entity Tax Identification Number 20-5566275
Entity Incorporation, State or Country Code CO
Entity Address, Address Line One 333 Las Olas Way,
Entity Address, Address Line Two CU4 Suite 433
Entity Address, City or Town Fort Lauderdale
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33301
City Area Code (954)
Local Phone Number 515-0810
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol SBFM
Security Exchange Name NASDAQ
Common Stock Purchase Warrants [Member]  
Title of 12(b) Security Common Stock Purchase Warrants
Trading Symbol SBFMW
Security Exchange Name NASDAQ
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://sunshinebiopharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports sbfm-20240909.xsd sbfm-20240909_def.xml sbfm-20240909_lab.xml sbfm-20240909_pre.xml sunshine_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "sunshine_8k.htm": { "nsprefix": "SBFM", "nsuri": "http://sunshinebiopharma.com/20240909", "dts": { "schema": { "local": [ "sbfm-20240909.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "sbfm-20240909_def.xml" ] }, "labelLink": { "local": [ "sbfm-20240909_lab.xml" ] }, "presentationLink": { "local": [ "sbfm-20240909_pre.xml" ] }, "inline": { "local": [ "sunshine_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 1, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 26 }, "report": { "R1": { "role": "http://sunshinebiopharma.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-09-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-09", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "sunshine_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "SBFM_CommonStockPurchaseWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://sunshinebiopharma.com/20240909", "localname": "CommonStockPurchaseWarrantsMember", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock Purchase Warrants [Member]" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://sunshinebiopharma.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001683168-24-006281-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001683168-24-006281-xbrl.zip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ƼC("VH&EQ\UT!87+G;>99FIQG#,-W M65H:SQGS;'M&LKR=("(";%=0BCPE1$H9I/W?8WK/-P]%\GS#64*(?,HJKWNK MOOMO Z/],O.B*K5I&A0:$6&>0YY\7!E3 ^)&A(R(B] ;8A'YP:+QL_@TJ@U$C.M#U6;[+ D@6 M[Y\_D27A&UL[9UM<^*V%L?? M=Z;?@4M?$R#IPTVZ:8>0T&&ZN^&&=+?MFQUA"]!$EAC)#O#M*YF' );DP]XL MQ^TT+Q("1]+Y_XXLZ]B2>?/S(N&U9ZHTD^*ZWCYKU6M41#)F8G)=_VW8Z R[ M_7Z]IE,B8L*EH-=U(>L___3U5S7S\^8_C4:MQRB/KVJW,FKTQ5C^6'M/$GI5 M^X4*JD@JU8^U#X1G]AW98YRJ6E]%DD$UB%PY2DF=[6UEJTUC^KXF\X$T]7 M]M>(:%HSO(2^6FAV7;?MKIN=7YQ)-6F>MUKMYN_OW@ZC*4U(@PG++:+U32E; MBZM<^_+RLIE_NC$M6"Y&BF_:N&ANW-G6;#YE ?L=3S2[TKE[;V5$TCSLI?*CJ^KNO1.#'-G'_;NFQ=VD:^V3-*ES/30S6S':Q> M:X(*HW[[SX MN'[CDSWYY9WOD8PX=3BZ-CRT._1V-ZX=M>\Y4=NN85[N!;5X0EE;-&=$F?H: MT93Q;7\8*YGX\*T;E$&OI3(]UTQS6BUTWJ;ST[YYJ0',=VR1N7NXAN'ON+\. MP'D% M#E1.O[\3"5T5-GP2!Q*!;Y.X:CJ&)[6& %9=>E6YD0)OS1<-E6+ R^ MKG40$9>2=2CP(B&31(K=IF;OAH M:G1/T_8M@+2_%&S_]&$#N^ Q"M:.:3^V/O0XF;BY'I@ P;91R3IE8:&]I3I2 M;&8!E1#>L\0>HX\#[1")-$(\T FSR89U9:LA/&1XBF"/V$<-(D'92*'H")$1 M_D!G4I5$8-\2"/[;2H!WB43B_;^,J)0JOH0@+Q@#J7]7">H>J5BS$C-!TLR" M@I O6@/1?U\)]#ZQ2.R'4\JYO29.!*C?N^R!_'^H!'^_X I$X.[93@:,&G@0 M=HH X_#?RL6A(!LI% .JF(R-# 4(0L$8B/^R$O@]4E'!WXD8BGUK"DZH*D3] M0"<2\Q[3$>$KCWKF/=>EX1W7'>90]KC9;*E>5/Y_4*+ ]'>,H>QQ$]P2K2.FLSYU*) W M%S-$:I=^A4 ?6D)AXV:Q(94HP+O&845X7\1T\2M=AH@73*'(<;/7H$X4Y@/% M$J*60Q:5CR=%6RAUW)PUK!0%^R-9]&/C-ANSU;K*(M @X":L(-THL>B+ M2*J9W+EJW969.4*771D'A_V2@M"XX&:R1S! B4XGC@TWO?YCE;1#,7&:@^]B M52 2 ;T5X7]^'/]S.'_<#+=4;T7X7QS'_P+.'S?++=6+R;]K7MZK1SGWW#[W M&D/9XV:Y)5HQR>?^WZN!DL]LM2FE#'^A!#0&54A^PZI1#X'5C #2_S>64/!5 M2(3=*C&!#Z1."?^3S^O+GJ /:ZB&^MU($)%#1N%NS4 M=6JV-M2*$G^'WK> DL5-;5VJ3@SVK;0W9:92!"\+%ZV@@'%S5)^Z4P_.=L>9 M]HX*.Q^#%^WA#KV'>D[,\Z-BJ?' KO;.Q/IZD.<&GL<4RADWL0SJ/#'S8;X% M,V5B\LYXKACA;N N.RAMW#32K_#$J >*VI!3,WW/5ZS9W:KJ?CSVCRAZ MW"RR7#%N"/I:9U0=&PA'*6@X<$"X+U*E4 ?T'SJ[9'YMBG[?"^5Y'[TS LW?X\IE#SR5M20SE,SSV*6 MTGCE4H\)(B*3HVUE>"X E)>"1@)YKRI0/F_/3ZN' M/8;0^TI (U"%&Y]AU4A+\E)JG]3%GNDM2IQ3L0[3U4(GH?W[*#@JY#RNA3B;$#+1IQ%/2Y)<'Z_9P8%787\UJ$/A?,- M$4\JFZ71TCY]FU)[7T=OCS] A@6L !J;*F2^1S'!N2+Q\B3,X=2HU_=9FG^] MAO$O>%TB6 X:HRHDQ1 "2',G_;)KCL8WRPP%UO>M'N$<9'P3 !+ M:@ #P '-U;G-H:6YE7SAK+FAT;>T]:U?BRK+?^15]V?>9V;-.)!T5U77NZH[\>0_ MTZ%&QLRR54/_]*>03/])F"X;BJKW/_U9ZI;K]3__'<^5+(T-304K_A(,JD5T'!764P(#CY,N3=#0YW(H3EWJ.,/56TC M*PI'K]'ACIA/F*X;*R#-L$)V?]9I+(8[T>,70U..176[9UA#ZH ($5(ND183 MXF$ 2,)F<@@0?$_VC?%WX>03&<&'LR*<\$KQMD3M.<<5ML1N'R?<@!EBUA\X MLA-]2LWYX!ZU)0[6N[$\V#(T9D>.YG="PQ7'2C@SD]G1A,/M%-[&.6(BG0FL M5C9&NF/-HI?@W0RALBUGE2BX&!K4/:M=S4?9(]T> /LEU3 '%!B?E(TA'YXN MI MQM#I&E=,8P3\GCNIH[#2?N#Q)N1]C)T/F4(+ $NQYI(X_QO)_B02IJ4Q3BJ3+G&/2I$-6)%-E>DSJ%?[A M(2U6'FZ[_Q(KYZ52&_Y#VD@BL>'D3.T!U_L0N,#M7>&"@ M>K *^%L:,EV!?TY-H_V''M5LM@6D7 !250=IS,H RJ):75?8])+-'M+@Z+)I M,2/F-P=[> :\KCP(#Y[/<.'#I2U B ]=X#"S'\0'[B%=&#:_M@48E'JE[8'* MK!"T#K9D*#-B.S.-?8KW0/F*1$B;#KE1AS"BR2:D8PRI?N!>. #\EMI#-5?4 ML3]-46U3H[,BT0V=X3UU6D1]91;8 ?^B*@K3T2CP&XQJCH8 1W:U?>IT6.]3 MO&2W>J@AB70!_L:)JGR*UZCLI/%/)DYT6#3@8FHQI CQ4ZX))ZD0Y!_!E0WB MBE25^.E"5Z(0IX)K1C(LUF,6A&AF\_OH=HLVCZ= #N%!LCBPD#);Z@T3OJ$D MI[82]VZCRX/;ZM#4&+H$#TT(LHO*-D:6APD&<;$7O<7SA2XMWO-5_DC&%^Q? MG%]6%;S14YE%..$L,C25ZY=AWBQ/GB-+16'S<)G 2$-9(0&2 \NI4(>=+JCW MX2SN+<\"55DSQ[^S1%(0NW_-8]]:EM8L8[A L/CTX(7#A[(Q'!IZUS'DIRLV ME)CU<]B^X"7KHP$MKGMW%*!D:FJJK#HNG40!N]=YHAGW%E/L.L VG%[6J W* MQ)=5FJIV_-0?LK+>DU0D^ !AJ4C*_E<411[9#@38 -_:8,4#R,WNJ 59GF/_ MH_4&_@ M_"X_EI%&@/5O!Y>_S$8OT"_BNIM@>!G620KFGL9BL1-SVSSNF RIU5?U(L&A MZ6.":I>@FMJ'2S)8"_J;$^GTMEF_J59(]Z9T4^V>I*33DY1YND-\I%LMWW;J M-_5JEY2:%5*]+U^4FN=54FY=7=6[W7JK.:=BAV3;Y3:MY0"K)GLE/].7Y$,"],0\O!//P(,ZX6U&'\^Z3 M%%)[ZDK'^_CW%E)Y9$%F[Y .,PW+V2DJ"+?V".(L<0R8)6,SB0@98EA$R.TI M^\3H$6? 8G!K9*F."MBJ4XC/>I^1DNS@;:&0R?[=&8[Q&=?B,ISL^=\9!6_, M;(>P,8R,6?PV4_:+!"PE9$HMCLA'24V86( M@W2-F8Z;YA4."&)::XT!H_Q[*\>R^$1/?&Z#H,/ZJHW=6 =[,VND=]7N2+=? M9MUQ/OZ:[]U-G=5;[8M2YZIT0.K-]V] MZA06P:E'P[3F5!-J$]MD,E8M"E%!4(Y-P$.!G5K[.R'I$0HVM3=;TCV'2AH# M 0]/_.B:288$*)&1#TZAI@^;XGWA* M?>)8/OPQLQQ5III/LF.87M9]XBC^( ]T)@.0@]H(5*U-C-[L\S(AHZGK,,GT MYO'BL.SVZ,N&LL:&IE\O!OU>K3IFVR46 0^(^RI8P3G,M(PQJM**"Q17#>15 M6B%6&QK<4XQ-_*"CK!5"]B.$D \)H:9J#*@%7Q[-\7;S9?I9J]S?=!_?[G$R MJPQ=X,46A)#("F)>_$'V?8@.ET/LNZ'3NMWI-43$3\5T(I<[/!2/J=+ MJD-3,V; W7J%-(UD".=<&U(\KKU[R1\=0S\F?PM[P9*B6,RVO?\:8/A"M FS MGM08:4^7CVK>=2-OM.+5EOEV1W6XR1+!$99OL['N2 5+SV8RKR:8'Z@>Y2B^E>%C MR[HQ)GHTUXQOLXRL?;NW>D\?D\D?K67Q@M3X:0VKV08= 3J%:BM;I1$Y_!:D M'Y!EUE6C6,==>SI/\6IXLT0",:418TTI< MW((9*[RH1/&B;4#ZJ7U3S?5Y[N'U;3]_?Z]\%7X@4RBLY42( NYDTL)/+N'W M/-*PKC,MD(]J4HVP*9-'CCK&<@^2&V;OD[T7U8S)0/=NZKJ/;"F\0R6%=EZR M&%VO2HW+BO-\*YC5O/1F51)#3:$@3A!<(9?=7Z,\*_:0\\AN&)!1M@>&_FKM MT1OF[JZ_ZHW[L[=3'FIV+*.-G^;XB3DA_;.U?]& ^?5$X.K9AG,9,I)7H MG-@#S$BU$781" 7VDW^ $1P3B]NQ-S&(K. 3V;4UHBX M)_F;(K@!4OPU%_3QG6H\$HO M2HPD;EF8R4QNA:8?H-BB/#IT9T/)T+8@=L><;'K]>L[(^(H7VM9 MC_$04[;CZ?HTYPV'#,.I4*BMO"]OSWFJ:2KD;MA_%.O=-YY?#XSV. 5QK_-\G8HC5!//,0F]SCL1L ME%$$UX[NRU;H\^L50N"4V,9_.,'DBEI/S"&-1OE'_5WIW?V=>RHU)+SHDYD/ M+[E2IF57!FK^)?/![F_CH[-AP>?X1ED=?L=7WGVTLUQ.+=['66XAUYM1TZY)RE4ZF]VU)#9VI4>_JBOU MMZ_>H43;:4]DOA]6'C!8#E:7U#0MP[14W B5C"F1F&9,L(['FUCMDWSBDO14 M#?-^U28J/CZH,"4&Y:JM#D>:0W5FC&QM1FQ(S.W>C,_T)A@2(.;YNE_-!H[4 M\ 2>4'WFW^M!T69,G%!QN])^K]+WG?FZ:K&^"[X#I006H=Z/=&^[W(YN M/WZ^F90J=F_2-9[>?-Q.,@R-49T_H[9D+J&-BDBRD"F%HVSV>(W!!'LJ'@ @ M+ @AU+[HC*">S8HY3[(HTD#/ P]R[@E'I%SK$#&33L+ ]^H(K=]][1K\.0[0 MJ2O0<%#SZ*CX\I5.+@:WC;%]F=N%*$([):LT;2.'Q6S@@3M]50A"EB8$,2 ' MWTN&I9!-)]V1NQ-$S1-$VV*H>_@D(3]FC4[$:O5ZZUKS\K?#ZSNCD;\M;;>K ML)E ,J']AO6T;2,8@)*0 V"^:RE"5DGP1A\74RPH)K(J)G?L[@25CA94W;9' MS/JNN,YGE^>-'JOHI==+K3>*2WA%7"L4[E9H&9;([LF;"WS-TI>W7P>[,.B( M$["1Q'W/EO]&0EMG;KU7# BW9)>L,<:M45W)IJ&R(DQCL@.VIAO<88ULQD.0BW%=K-U9=U>5F:/SO>R@J:9)'/1_HK>\?T+!A=0X%T;;=IGQS#Z M>83A!X#R-V;P[D[@[1 #)M2"Z55[;3EO;C5ML8KS85PQ:@L1Z?$7'*>L%[K+*WV$X* MOLQP4?ZBJ1D44F5_7>;(.N;QC%IF3S.%\D%?YT&"L!#'0"5\F'A[74T M999HLM3^P DO!-L%?J_ >ZIV6=B2Q>A30F)@ET"ER15D,P4PP_K"U2ZHPT&$ MP;4A)[C>_3V\*#_55'?8D.23:8&T>$Y2Q>?F[.3.3M%\:$!HZ63E\3< X+TO MB9SY+TPZ('5=3L;VT*_BF1XQ?>P%3?Y-.-X'_RTS=0R.F8*U0?5ND9YE#+DG M=AME*WTMS),X*/?^'!*$_)YJ#3%(. /J-HP\>*"!\C2/!Q,5W[+F1A,< M**D*'KF3,5X]CU3+S;0A(6Q \$*0/)W+Y7)I"!5[XCX)KND,)K?Y9!SE$W2 MJ:4'3<'8B#,N&+4P,K6ISK3Y,2=_1?.K?$$*DWF#B>#SB@KY/ +6BGF7VW^G M5' -#NPX^R(?6=Q(^"-)]JKX)JJFQ21&[)'T"#$;8S<%C8#8[AC6C'"VD2M# M5QWWP _<]9('".IX>@R?\DR2>N^ 2QS$RE' G03>(4-W*F_K\7D'007T5>!Z M!$OP'R^Q,;GH]9:4$905+LXE"$F)8H=60E$'B3'B67^4(H9UZ6"%#3QQ E8 MG4/L=O$NIY?=N!4+)\M-DXBI43T*D\7P24'.2,X)K(!D%>('4*@K$'T.^!ZF%@:[);8'] /!9+N(@*" ",*(KV F2DU\]8F; M38PL?LIK@2+F27ZE+,[EA314NGN9?= $W788#8LYL&@5ZW5@7X5I('OXS\'E MZVZ7N.'J+/)I13@#.F9(H6'B<3)\><4LQOD P1D 49ZU#EP?L)"Y"N,PT.\U#H\#PK%D4['5-60,TERLVQ G#B<%Z#.E9)M M&KJ2,N$#TSVQL&6<-)!$@S,+^\4\?T9^+[N_5]X/89Z[.'O191U2+E&%,Q=3 M=W3XGA"XX>,/T*CW\G$?X<[FQ];^$ 4Q)Q9^X_R-\S?.37%^,#9IOLA=)^/X M>,,"R2MUM1A95W^O"-Y=W?V/KZN1W^+O"OJ]-?UC'AGJUL^;I9O;3N!-7#O$ M]C'.8N7\44[5PV\E0.@9F,CW3%B'!P=.0,HHEZ8LM/J-)I1'WS0 M_T<.[>=P.KY$B+LJOXTBI/W7"*T_I,YGHOY[KZ8A*Z^F>>L[# (>+.K:+PGO M;%8D&Y^_3]DI4K&24.4QJ(*:\$�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end XML 16 sunshine_8k_htm.xml IDEA: XBRL DOCUMENT 0001402328 2024-09-09 2024-09-09 0001402328 us-gaap:CommonStockMember 2024-09-09 2024-09-09 0001402328 SBFM:CommonStockPurchaseWarrantsMember 2024-09-09 2024-09-09 iso4217:USD shares iso4217:USD shares false 0001402328 8-K 2024-09-09 SUNSHINE BIOPHARMA, INC. CO 001-41282 20-5566275 333 Las Olas Way, CU4 Suite 433 Fort Lauderdale FL 33301 (954) 515-0810 Common Stock, par value $0.001 SBFM NASDAQ Common Stock Purchase Warrants SBFMW NASDAQ false false false false false